A novel adapter-programmable hydrogel matrix for integrated CAR T cell manufacturing (CAR-AdMATRIX)

Cancer is one of the most common causes of death worldwide. Chimeric antigen receptor (CAR) T cell therapy is a promising treatment method for certain types of cancer. However, its widespread use is limited, as the therapeutic cells are often unable to develop their effect in patients for long enough. The therapy is also very expensive and therefore not accessible to everyone. With the "CAR-AdMATRIX" project, Prof. Dr. Jörg Mittelstät aims to improve the immunological memory and effectiveness of CAR-T cells using a novel culture method. The aim is to develop a programmable matrix based on a hydrogel in order to simulate the physiological activation of T cells. The use of a single matrix for the stimulation, modification and cultivation of the cells drastically simplifies the production process. The aim of the planned development is to contribute to an improved and more cost-effective CAR-T cell therapy against cancer.